Aravive to Host Virtual KOL Event on its Late-Stage Oncology Asset Batiraxcept
May 08, 2023 07:05 ET
|
Aravive, Inc.
HOUSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting
April 26, 2023 17:00 ET
|
Aravive, Inc.
HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
Aravive Appoints Carolina Petrini as Chief Commercial Officer
April 11, 2023 07:05 ET
|
Aravive, Inc.
HOUSTON, April 11, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
March 15, 2023 07:00 ET
|
Aravive, Inc.
HOUSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
Aravive Announces FDA Orphan Drug Designation Granted to Batiraxcept for the Treatment of Pancreatic Cancer
February 28, 2023 16:05 ET
|
Aravive, Inc.
Dose escalation portion of ongoing Phase 1b/2 pancreatic adenocarcinoma trial initiated, with preliminary results expected in 2H 2023 HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc....
Aravive to Present Positive Updated Data from Phase 1b Trial of Batiraxcept in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma at the 2023 ASCO Genitourinary (GU) Cancers Symposium
February 13, 2023 17:00 ET
|
Aravive, Inc.
HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
Aravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer
January 04, 2023 07:05 ET
|
Aravive, Inc.
Topline data expected mid-2023Potential Biologics License Application (BLA) submission end of 2023 HOUSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late...
Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC
November 29, 2022 07:00 ET
|
Aravive, Inc.
HOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
Aravive To Participate in Piper’s 34th Annual Healthcare Conference
November 21, 2022 07:00 ET
|
Aravive, Inc.
HOUSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that...
Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement
November 16, 2022 07:00 ET
|
Aravive, Inc.
HOUSTON, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...